成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Annals of palliative medicine >>article
Annals of palliative medicine

Annals of palliative medicine

Download PDF

The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.

Published:1 October 2021 DOI: 10.21037/apm-21-1564 PMID: 34498481
Meijiao Wang, Yi Zhang, Min Zhang, Haichang Li, Chengping Wen, Ting Zhao, Zhijun Xie, Jing Sun

Abstract

Background: To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia.

Methods: Relevant studies published until August 15, 2020 were identified by a systematic search of the PubMed and Wiley Online Library databases. Any controlled clinical trial, randomised controlled trial (RCT), retrospective cohort study or open label trial (OLT) comparing febuxostat in patients with gout or hyperuricemia with allopurinol. The quality of all identified studies was assessed based on Cochrane Collaboration's risk of bias tool. Odds ratios (OR) were calculated with random effects and reported with corresponding 95% confidence intervals (CI).

Results: Eighteen studies were ultimately included in the analysis, among them 6 articles mentioned serum uric acid (sUA) level before and after treatment, 14 articles mentioned major cardiovascular events, 5 articles mentioned cardiovascular death, 6 articles mentioned skin reactions, 6 articles mentioned musculoskeletal and connective tissue signs and symptoms, 4 articles mentioned joint-related signs and symptoms, 6 articles mentioned upper respiratory infection, 5 articles mentioned gastrointestinal reaction and 7 articles mentioned all-cause mortality. The febuxostat group showed significantly lower sUA levels than allopurinol group (MD =-0.83, 95% CI: -1.22 to -0.44, P<0.0001, I2=98%). There was no markedly difference between the febuxostat and allopurinol (OR 1.01, 95% CI: 0.83 to 1.23, P=0.84, I2=95%) in the major cardiovascular events. The occurrence of skin reactions of febuxostat was significantly fewer than allopurinol (OR 0.55, 95% CI: 0.42 to 0.73, P<0.0001, I2=49%). Regarding to occurrence of CV death, musculoskeletal and connective tissue signs and symptoms, febuxostat group was higher than allopurinol group. However, among patients with gout or hyperuricemia, treatment with febuxostat resulted in other adverse reactions, including all-causes mortality similar to those associated with allopurinol.

Discussion: The limitation of the study was the included studies show high heterogeneity in regard to their design. There was no difference in the incidence of major cardiovascular events between febuxostat and allopurinol, and febuxostat was better in lowering uric acid and has less adverse skin reactions than allopurinol, but the risk of CV death of febuxostat was higher than allopurinol.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Febuxostat 144060-53-7 C16H16N2O3S 871 suppliers $5.00-$5690.00
Allopurinol 315-30-0 C5H4N4O 858 suppliers $5.00-$2285.00

Similar articles

IF:2.4

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis

Clinical Cardiology Linggen Gao MD, Bin Wang MD,etc Published: 20 May 2021
IF:20.3

Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis.

Annals of the Rheumatic Diseases Xingzhong Jin, Julieta Ruiz Beguerie,etc Published: 1 April 2015
IF:9.3

Effects of Creatine Monohydrate on Endurance Performance in a Trained Population: A Systematic Review and Meta-analysis.

Sports Medicine Julen Fernández-Landa, Asier Santiba?ez-Gutierrez,etc Published: 1 May 2023